OA10564A - A pharmaceutical preparation for topical administration of antigens and/or vaccines to mammals via amucosal membrane - Google Patents
A pharmaceutical preparation for topical administration of antigens and/or vaccines to mammals via amucosal membrane Download PDFInfo
- Publication number
- OA10564A OA10564A OA60698A OA60698A OA10564A OA 10564 A OA10564 A OA 10564A OA 60698 A OA60698 A OA 60698A OA 60698 A OA60698 A OA 60698A OA 10564 A OA10564 A OA 10564A
- Authority
- OA
- OAPI
- Prior art keywords
- vaccines
- pharmaceutical preparation
- antigens
- preparation according
- caprylic
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/05—Actinobacteria, e.g. Actinomyces, Streptomyces, Nocardia, Bifidobacterium, Gardnerella, Corynebacterium; Propionibacterium
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/08—Clostridium, e.g. Clostridium tetani
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/145—Orthomyxoviridae, e.g. influenza virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0043—Nose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
- A61K2039/541—Mucosal route
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
- A61K2039/541—Mucosal route
- A61K2039/543—Mucosal route intranasal
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55505—Inorganic adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/70—Multivalent vaccine
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/16011—Orthomyxoviridae
- C12N2760/16111—Influenzavirus A, i.e. influenza A virus
- C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Microbiology (AREA)
- Virology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Pulmonology (AREA)
- Otolaryngology (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DK93170A DK17093D0 (da) | 1993-02-15 | 1993-02-15 | Farmaceutisk praeparat til topisk administrering af antigener og/eller vacciner til pattedyr via slimhinder |
Publications (1)
Publication Number | Publication Date |
---|---|
OA10564A true OA10564A (en) | 2002-06-20 |
Family
ID=8090567
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
OA60698A OA10564A (en) | 1993-02-15 | 1995-08-11 | A pharmaceutical preparation for topical administration of antigens and/or vaccines to mammals via amucosal membrane |
Country Status (14)
Country | Link |
---|---|
US (1) | US5942237A (de) |
EP (1) | EP0682528B1 (de) |
JP (1) | JPH09508614A (de) |
AT (1) | ATE195077T1 (de) |
AU (1) | AU668290B2 (de) |
CA (1) | CA2156084A1 (de) |
DE (1) | DE69425427T2 (de) |
DK (2) | DK17093D0 (de) |
ES (1) | ES2150982T3 (de) |
GR (1) | GR3034727T3 (de) |
NO (1) | NO312057B1 (de) |
OA (1) | OA10564A (de) |
PT (1) | PT682528E (de) |
WO (1) | WO1994017827A1 (de) |
Families Citing this family (46)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB9316745D0 (en) * | 1993-08-12 | 1993-09-29 | Medeva Holdings Bv | Vaccine compositions |
EP0915707B1 (de) * | 1996-01-25 | 2002-10-30 | Profylakse ApS | Pharmazeutische zusammensetzung, enthaltend serum-amyloid p-komponenten, zur prophylaxe und therapie von viralen infektionen sowie kit zur detektionvon komplexen zwischen solchen zusammensetzungen und viralen komponenten |
IS4518A (is) | 1997-07-09 | 1999-01-10 | Lyfjathroun Hf, The Icelandic Bio Pharmaceutical Group | Nýtt lyfjaform fyrir bóluefni |
CA2325939A1 (en) * | 1998-04-09 | 1999-10-21 | Martin Friede | Vaccine |
US7229621B2 (en) * | 1998-10-20 | 2007-06-12 | Torrey Pines Institute For Molecular Studies | Method to enhance the immunogenicity of an antigen |
SE9900495D0 (sv) * | 1999-02-12 | 1999-02-12 | Pharmatrix Ab | Vaccine composition |
EP1034792A1 (de) * | 1999-03-11 | 2000-09-13 | Pasteur Merieux Serums Et Vaccins | Intranasale Verabreichung von Pneumokokken-Polysaccharid Impfstoffen |
ES2293923T3 (es) * | 1999-09-24 | 2008-04-01 | Glaxosmithkline Biologicals S.A. | Vacuna intranasal contra el virus influenza. |
GB9924351D0 (en) | 1999-10-14 | 1999-12-15 | Brennan Frank | Immunomodulation methods and compositions |
WO2004030608A2 (en) * | 2001-06-05 | 2004-04-15 | The Regents Of The University Of Michigan | Nanoemulsion vaccines |
CA2457595A1 (en) * | 2001-08-16 | 2003-02-27 | Lyfjathroun H.F., Biopharmaceuticals | A method of producing antibodies ex-vivo |
KR100406503B1 (ko) * | 2001-09-25 | 2003-11-19 | 한국과학기술연구원 | 폐렴구균성 표면 접착단백질의 가용화용 조성물, 가용화용액상제형, 및 가용화용 분말제형, 이들 각각의 제조방법및 백신 |
EP1521599A2 (de) * | 2002-02-25 | 2005-04-13 | Lyfjathroun HF, Biopharmaceutical Research | Mittel zur verbesserung der absorption |
US6855332B2 (en) * | 2002-07-03 | 2005-02-15 | Lyfjathroun Hf. | Absorption promoting agent |
AU2002352938B8 (en) | 2002-11-26 | 2009-10-08 | The University Of Chicago | Materials and methods for preventing and treating microbe-mediated epithelial disorders |
US9717754B2 (en) * | 2003-02-27 | 2017-08-01 | Enzo Therapeutics, Inc. | Glucocerebroside treatment of disease |
US20070184058A1 (en) * | 2003-02-27 | 2007-08-09 | Yaron Ilan | Glucocerebroside treatment of pulmonary or respiratory diseases or disorders |
WO2005032462A2 (en) | 2003-02-27 | 2005-04-14 | Enzo Therapeutics, Inc. | Glucocerebroside treatment of disease |
US20050208083A1 (en) * | 2003-06-04 | 2005-09-22 | Nanobio Corporation | Compositions for inactivating pathogenic microorganisms, methods of making the compositons, and methods of use thereof |
CN101084016A (zh) | 2004-04-15 | 2007-12-05 | 克艾思马有限公司 | 能够容易穿透生物学障碍的组合物 |
EP1843787B1 (de) * | 2005-01-28 | 2011-11-02 | North-West University | Lipid- und distickstoffoxidverbindung als hilfsmittel zur erhöhung der impfstoffeffizienz |
EP1871349A1 (de) * | 2005-04-11 | 2008-01-02 | Nanobio Corporation | Quartäre ammoniumhalogenide zur behandlung von infektionskrankheiten |
EP1951200A2 (de) * | 2005-08-09 | 2008-08-06 | Nanobio Corporation | Eine nanoemulsion enthaltende zusammensetzungen mit entzündungshemmender wirkung |
US9839685B2 (en) * | 2006-04-13 | 2017-12-12 | The Regents Of The University Of Michigan | Methods of inducing human immunodeficiency virus-specific immune responses in a host comprising nasally administering compositions comprising a naonemulsion and recombinant GP120 immunogen |
US10138279B2 (en) | 2006-04-13 | 2018-11-27 | Regents Of The University Of Michigan | Compositions and methods for Bacillus anthracis vaccination |
US20080038295A1 (en) * | 2006-04-13 | 2008-02-14 | Regents Of The University Of Michigan | Compositions and methods for orthopox virus vaccination |
TW200824693A (en) * | 2006-08-28 | 2008-06-16 | Jazz Pharmaceuticals Inc | Pharmaceutical compositions of clonazepam and methods of use thereof |
US20100047327A1 (en) * | 2007-01-31 | 2010-02-25 | Tetsuji Kuwahara | Adjuvant for Transdermal or Transmucosal Administration and Pharmaceutical Preparation Containing the Same |
EP2139993A2 (de) * | 2007-04-27 | 2010-01-06 | Dow Global Technologies Inc. | Verbesserte herstellung und in-vivo-synthese löslicher und rekombinanter virusähnlicher partikel in ikosaeder-form |
CA2826508C (en) | 2008-05-23 | 2016-07-19 | The Regents Of The University Of Michigan | Nanoemulsion vaccines |
CA2963659C (en) | 2008-09-17 | 2020-06-23 | Chiasma Inc. | Use of oral octreotride compositions |
JP6110140B2 (ja) * | 2009-06-16 | 2017-04-05 | ザ リージェンツ オブ ザ ユニヴァシティ オブ ミシガン | ナノエマルションワクチン |
EP2550362B1 (de) | 2010-03-25 | 2017-01-04 | Oregon Health&Science University | Cmv-glycoproteine und rekombinante vektoren |
WO2012170765A2 (en) | 2011-06-10 | 2012-12-13 | Oregon Health & Science University | Cmv glycoproteins and recombinant vectors |
EP2568289A3 (de) | 2011-09-12 | 2013-04-03 | International AIDS Vaccine Initiative | Immunselektion von rekombinantem vesikulärem Stomatitisvirus mit Expression von HIV-1-Proteinen durch Breitbandneutralisierungs-Antikörper |
EP2586461A1 (de) | 2011-10-27 | 2013-05-01 | Christopher L. Parks | Von einem eingehüllten Virus abgeleitete Virenpartikel |
EP2679596B1 (de) | 2012-06-27 | 2017-04-12 | International Aids Vaccine Initiative | HIV-1 Env-proteinvariante |
EP2848937A1 (de) | 2013-09-05 | 2015-03-18 | International Aids Vaccine Initiative | Verfahren zur Identifizierung neuartiger HIV-1-Immunogene |
EP2873423B1 (de) | 2013-10-07 | 2017-05-31 | International Aids Vaccine Initiative | Lösliche hiv-1-hüllglykoproteintrimere |
WO2015064710A1 (ja) | 2013-10-31 | 2015-05-07 | 久光製薬株式会社 | アジュバント組成物、これを含むアジュバント製剤、及びキット |
US10525088B2 (en) | 2014-05-30 | 2020-01-07 | Kirin Holdings Kabushiki Kaisha | Lactic acid bacterial immunopotentiating activity-increasing composition and method for increasing immunopotentiating activity of lactic acid bacteria |
CA2975599A1 (en) | 2015-02-03 | 2016-08-11 | Chiasma Inc. | Method of treating diseases |
US10174292B2 (en) | 2015-03-20 | 2019-01-08 | International Aids Vaccine Initiative | Soluble HIV-1 envelope glycoprotein trimers |
US9931394B2 (en) | 2015-03-23 | 2018-04-03 | International Aids Vaccine Initiative | Soluble HIV-1 envelope glycoprotein trimers |
CN111721937B (zh) * | 2019-03-29 | 2023-04-07 | 北京九强生物技术股份有限公司 | 人附睾蛋白4免疫比浊试剂盒 |
US11141457B1 (en) | 2020-12-28 | 2021-10-12 | Amryt Endo, Inc. | Oral octreotide therapy and contraceptive methods |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB1171125A (en) * | 1966-06-08 | 1969-11-19 | Glaxo Lab Ltd | Improvements in or relating to Injectable Preparations |
US4315925A (en) * | 1980-05-30 | 1982-02-16 | University Of Kentucky Research Foundation | Method of administering natural female sex hormones |
DE3446515A1 (de) * | 1984-12-20 | 1986-06-26 | Behringwerke Ag, 3550 Marburg | Oeladjuvierte vaccine und verfahren zu ihrer herstellung |
JPS61194034A (ja) * | 1985-02-25 | 1986-08-28 | Teijin Ltd | 経鼻投与用粉末状組成物 |
JP2849632B2 (ja) * | 1988-04-08 | 1999-01-20 | 社団法人北里研究所 | ワクチン製剤 |
NL9000207A (de) * | 1990-01-29 | 1991-08-16 | Duphar Int Res | |
GB9018690D0 (en) * | 1990-08-24 | 1990-10-10 | Wellcome Found | Vaccines |
DK0580778T3 (da) * | 1991-04-19 | 2000-01-31 | Lds Technologies Inc | Konvertible mikroemulsionsformuleringer |
DK0534618T3 (da) * | 1991-08-26 | 2006-07-24 | Scripps Research Inst | Peptider til fremkaldelse af cytotoksiske T-lymfocytreaktioner mod hepatitis B-virus |
CA2083553A1 (en) * | 1991-11-25 | 1993-05-26 | Kuniharu Seki | Immunogen composition |
-
1993
- 1993-02-15 DK DK93170A patent/DK17093D0/da not_active Application Discontinuation
-
1994
- 1994-02-14 WO PCT/DK1994/000062 patent/WO1994017827A1/en active IP Right Grant
- 1994-02-14 DK DK94907503T patent/DK0682528T3/da active
- 1994-02-14 ES ES94907503T patent/ES2150982T3/es not_active Expired - Lifetime
- 1994-02-14 DE DE69425427T patent/DE69425427T2/de not_active Expired - Fee Related
- 1994-02-14 PT PT94907503T patent/PT682528E/pt unknown
- 1994-02-14 JP JP6517549A patent/JPH09508614A/ja not_active Ceased
- 1994-02-14 AU AU61065/94A patent/AU668290B2/en not_active Ceased
- 1994-02-14 CA CA002156084A patent/CA2156084A1/en not_active Abandoned
- 1994-02-14 US US08/501,112 patent/US5942237A/en not_active Expired - Fee Related
- 1994-02-14 EP EP94907503A patent/EP0682528B1/de not_active Expired - Lifetime
- 1994-02-14 AT AT94907503T patent/ATE195077T1/de not_active IP Right Cessation
-
1995
- 1995-08-11 OA OA60698A patent/OA10564A/en unknown
- 1995-08-14 NO NO19953182A patent/NO312057B1/no unknown
-
2000
- 2000-10-30 GR GR20000402416T patent/GR3034727T3/el not_active IP Right Cessation
Also Published As
Publication number | Publication date |
---|---|
EP0682528B1 (de) | 2000-08-02 |
DK17093D0 (da) | 1993-02-15 |
AU668290B2 (en) | 1996-04-26 |
JPH09508614A (ja) | 1997-09-02 |
NO953182L (no) | 1995-10-12 |
US5942237A (en) | 1999-08-24 |
DE69425427D1 (de) | 2000-09-07 |
DK0682528T3 (da) | 2000-12-27 |
NO953182D0 (no) | 1995-08-14 |
EP0682528A1 (de) | 1995-11-22 |
DE69425427T2 (de) | 2001-02-08 |
GR3034727T3 (en) | 2001-01-31 |
AU6106594A (en) | 1994-08-29 |
ES2150982T3 (es) | 2000-12-16 |
NO312057B1 (no) | 2002-03-11 |
ATE195077T1 (de) | 2000-08-15 |
PT682528E (pt) | 2001-01-31 |
CA2156084A1 (en) | 1994-08-18 |
WO1994017827A1 (en) | 1994-08-18 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
OA10564A (en) | A pharmaceutical preparation for topical administration of antigens and/or vaccines to mammals via amucosal membrane | |
US6391318B1 (en) | Vaccine compositions including chitosan for intranasal administration and use thereof | |
Claassen et al. | The iscom structure as an immune enhancing moiety: experience with viral systems. | |
Glück | Immunopotentiating reconstituted influenza virosomes (IRIVs) and other adjuvants for improved presentation of small antigens | |
EP0988053A1 (de) | Gereinigte saponinen als orale adjuvantien | |
EP2231145B1 (de) | Verwendung von glycosylceramiden für die verstärkung der immunantwort auf antigene | |
US20020009463A1 (en) | Novel, non-antigenic, mucosal adjuvant formulation which enhances the effects of substances, including vaccine antigens, in contact with mucosal body surfaces | |
US6890540B1 (en) | Vaccine formulation | |
KR20030015288A (ko) | 보조제 배합물로서의 큐에스-21 및 아이엘-12 | |
Li et al. | iNKT cell agonists as vaccine adjuvants to combat infectious diseases | |
WO2001098206A1 (en) | Delivery vehicle composition and methods for delivering antigens and other drugs | |
AU2008360937B2 (en) | Methods of enhancing adjuvanticity of vaccine compositions | |
Ferreira et al. | Glycoside based adjuvants |